Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)
NCT ID: NCT01078987
Last Updated: 2014-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
12 participants
INTERVENTIONAL
2002-02-28
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
One to three 5-day course of plasma exchange (plasmapheresis)
Plasmapheresis
A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
Group 2
One to three 5-day course of plasma exchange (plasmapheresis)
Plasmapheresis
A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
Group 3
No intervention taken
No interventions assigned to this group
Group 4
One to three 5-day course of plasma exchange (plasmapheresis)
Plasmapheresis
A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plasmapheresis
A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosed with NFD/NSF following a liver transplant
* NFD/NSF and who have not had a kidney or liver transplant
* diagnosed with NFD/NSF and who have not had a kidney or liver transplant
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Loma Linda University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pedro Baron, MD
Role: PRINCIPAL_INVESTIGATOR
Loma Linda University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Loma Linda University Medical Center
Loma Linda, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
51018
Identifier Type: -
Identifier Source: org_study_id